BR112015023761A2 - moduladores de molécula pequena de pcsk9 e seus métodos e usos - Google Patents
moduladores de molécula pequena de pcsk9 e seus métodos e usosInfo
- Publication number
- BR112015023761A2 BR112015023761A2 BR112015023761A BR112015023761A BR112015023761A2 BR 112015023761 A2 BR112015023761 A2 BR 112015023761A2 BR 112015023761 A BR112015023761 A BR 112015023761A BR 112015023761 A BR112015023761 A BR 112015023761A BR 112015023761 A2 BR112015023761 A2 BR 112015023761A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- small molecule
- molecule modulators
- compound
- pcsk9
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Crystallography & Structural Chemistry (AREA)
Abstract
resumo da patente de invenção para: “moduladores de molécula pequena de pcsk9 e seus métodos e usos”. um composto da fórmula (i): ou sal, hidrato, solvato, mistura racêmica ou estereoisômero farmaceuticamente aceitável do mesmo, e métodos para prevenção e tratamento de um doença ou distúrbio relacionado ao colesterol ldl usando este(s) composto(s), bem como kits e composições que compreendem este(s) composto(s).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792249P | 2013-03-15 | 2013-03-15 | |
PCT/CA2014/050255 WO2014139008A1 (en) | 2013-03-15 | 2014-03-14 | Small molecule modulators of pcsk9 and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015023761A2 true BR112015023761A2 (pt) | 2017-07-18 |
Family
ID=51535727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015023761A BR112015023761A2 (pt) | 2013-03-15 | 2014-03-14 | moduladores de molécula pequena de pcsk9 e seus métodos e usos |
Country Status (10)
Country | Link |
---|---|
US (1) | US20160031935A1 (pt) |
EP (1) | EP2961765A4 (pt) |
JP (1) | JP2016511274A (pt) |
KR (1) | KR20150132362A (pt) |
CN (1) | CN105431447A (pt) |
AU (1) | AU2014231330A1 (pt) |
BR (1) | BR112015023761A2 (pt) |
CA (1) | CA2905237A1 (pt) |
HK (1) | HK1222864A1 (pt) |
WO (1) | WO2014139008A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3160513T3 (da) | 2014-06-30 | 2020-04-06 | Glykos Finland Oy | Saccharidderivat af en toksisk payload og antistofkonjugater deraf |
JP2017528448A (ja) * | 2014-08-21 | 2017-09-28 | エスアールエックス カーディオ,エル エル シー | プロタンパク質コンバターゼであるスブチリシン/ケキシンタイプ9(pcsk9)のタンパク質活性のモジュレーションのための、結合リガンドとしての小分子の組成物およびその使用方法 |
WO2016040305A1 (en) * | 2014-09-08 | 2016-03-17 | Temple University-Of The Commonwealth System Of Higher Education | Pcsk9 inhibitors and methods of use thereof |
EP3973958A3 (en) * | 2015-03-20 | 2022-06-22 | Aarhus Universitet | Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders |
AU2017273857B2 (en) | 2016-06-01 | 2021-08-19 | Athira Pharma, Inc. | Compounds |
KR102449308B1 (ko) | 2016-06-24 | 2022-10-04 | 에프. 호프만-라 로슈 아게 | 심혈관 질환의 치료를 위한 조성물 및 방법 |
GB2567210B (en) | 2017-10-06 | 2020-01-15 | Rolls Royce Plc | A bladed disk |
CN109096247A (zh) * | 2018-08-15 | 2018-12-28 | 上海罕道医药科技有限公司 | 一种3h双吖丙啶基双取代吡啶衍生物的制备方法 |
CN113574055A (zh) | 2019-01-18 | 2021-10-29 | 阿斯利康(瑞典)有限公司 | Pcsk9抑制剂及其使用方法 |
LV15544A (lv) * | 2019-07-01 | 2021-01-20 | Latvijas Organiskās Sintēzes Institūts | Jauni borskābi saturoši peptidomimētiķi kā malārijas serīna proteāzes inhibitori |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0929642A1 (en) * | 1996-09-24 | 1999-07-21 | The Procter & Gamble Company | Liquid laundry detergent compositions containing proteolytic enzyme and protease inhibitors |
GB9623908D0 (en) * | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
US6358491B1 (en) * | 1999-08-27 | 2002-03-19 | Berlex Laboratories, Inc. | Somatostatin analogs |
JP2005531540A (ja) * | 2002-04-30 | 2005-10-20 | トラスティーズ・オブ・タフツ・カレッジ | セリンプロテアーゼ阻害剤のスマートプロドラッグ |
EP2137218A2 (en) * | 2007-04-13 | 2009-12-30 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9) |
AR079344A1 (es) * | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
MA34133B1 (fr) * | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
US8999922B2 (en) * | 2012-02-16 | 2015-04-07 | Rqx Pharmaceuticals, Inc. | Linear peptide antibiotics |
-
2014
- 2014-03-14 CA CA2905237A patent/CA2905237A1/en not_active Abandoned
- 2014-03-14 BR BR112015023761A patent/BR112015023761A2/pt active Search and Examination
- 2014-03-14 EP EP14765405.7A patent/EP2961765A4/en not_active Withdrawn
- 2014-03-14 WO PCT/CA2014/050255 patent/WO2014139008A1/en active Application Filing
- 2014-03-14 AU AU2014231330A patent/AU2014231330A1/en not_active Abandoned
- 2014-03-14 CN CN201480026888.4A patent/CN105431447A/zh active Pending
- 2014-03-14 KR KR1020157029032A patent/KR20150132362A/ko not_active Application Discontinuation
- 2014-03-14 JP JP2015561865A patent/JP2016511274A/ja active Pending
- 2014-03-14 US US14/776,701 patent/US20160031935A1/en not_active Abandoned
-
2016
- 2016-09-19 HK HK16110987.6A patent/HK1222864A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20160031935A1 (en) | 2016-02-04 |
EP2961765A4 (en) | 2016-11-09 |
CN105431447A (zh) | 2016-03-23 |
KR20150132362A (ko) | 2015-11-25 |
AU2014231330A1 (en) | 2015-10-01 |
CA2905237A1 (en) | 2014-09-18 |
WO2014139008A1 (en) | 2014-09-18 |
EP2961765A1 (en) | 2016-01-06 |
JP2016511274A (ja) | 2016-04-14 |
HK1222864A1 (zh) | 2017-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015023761A2 (pt) | moduladores de molécula pequena de pcsk9 e seus métodos e usos | |
PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
BR112015001502A2 (pt) | derivados de tipo azaindazol ou diazaindazol para tratamento de dor | |
BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
BR112017007662A2 (pt) | composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto | |
EA201690044A1 (ru) | Модуляторы ядерного транспорта и их применение | |
BR112015014034A2 (pt) | inibidores de irak e usos dos mesmos | |
EA201990240A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
NI201300073A (es) | Compuestos y composiciones como inhibidores de la trk | |
CO6501189A2 (es) | Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos | |
CL2012002319A1 (es) | Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras. | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
CO7310528A2 (es) | Composición farmacéutica recubierta que contiene regorafenib | |
BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
ECSP14007965A (es) | Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetil aminoisoindolin-1, 3-diona | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
EA201691293A1 (ru) | Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h | |
BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
NZ748769A (en) | Nitroxyl donors with improved therapeutic index | |
BR112017003745A2 (pt) | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico | |
BR112015019587A2 (pt) | combinações compreendendo compostos maba e corticosteroides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |